Stock Track | Travere Therapeutics Plummets 5.43% Intraday as FDA Delays Review of Key Kidney Drug

Stock Track01-14

Travere Therapeutics, Inc. (NASDAQ: TVTX) saw its stock plummet by 5.43% during the intraday session on Wednesday, as investors reacted to the U.S. Food and Drug Administration (FDA) extending the review timeline for its supplemental New Drug Application (sNDA) for Filspari, a treatment for focal segmental glomerulosclerosis (FSGS).

The FDA's delay, which pushes the target action date to April 13, has raised concerns among investors about the drug's approval timeline. Filspari is a critical product for Travere, as it would be the first medication indicated for FSGS, a rare and serious kidney disorder. The company recently submitted responses to the FDA's requests for additional information to characterize the clinical benefit of Filspari, but no further details on safety or manufacturing were required.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment